Carmelo Gurnari, MD, PhD, is a dedicated hematologist currently serving as an Associate
Professor of Hematology at the University of Tor Vergata in Rome, Italy and as a Project
Staff in the Department of Translational Hematology and Oncology Research at the
Cleveland Clinic (USA).
Dr. Gurnari earned his medical degree from the University of Pavia, Italy, in 2015, and
completed his Hematology training at Tor Vergata University in 2020. He joined the
Cleveland Clinic in 2019, where he also completed a Ph.D. in "Immunology, Molecular
Medicine, and Applied Biotechnology," subsequently being appointed to the faculty.
His long-term research interests focus on unraveling the ontogenetic mechanisms of
leukemia using cutting-edge molecular biology sequencing platforms, with the ultimate
goal of informing early therapeutic interventions. Specifically, he studies the genomics of
bone marrow failure disorders and myeloid neoplasia, including germline predisposition,
while pioneering efforts to translate genomic information into clinical practice.
Dr. Gurnari has made significant contributions to his field, having authored over 160
papers in prestigious journals. He has secured national and international grants from
organizations such as the EvansMDS Foundation, the American-Italian Cancer
Foundation, and the European Hematology Association. Additionally, he has received
several accolades, including the Tito Bastianello Prize at the 2021 International MDS
Symposium and the ASH-IPIG Award on two occasions.